Ubs Oconnor LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Ubs Oconnor LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.0 - $44.96 $0 - $89.9 Million	-2,000,000 Closed	0 $0
Q2 2024 Nov 14, 2024	SELL	$38.96 - $42.75 $47.9 Million - $52.6 Million	-1,230,529 Reduced 38.09%	2,000,000 $81.8 Billion
Q1 2024 Nov 14, 2024	BUY	$40.88 - $43.27 $61.5 Million - $65.1 Million	1,505,529 Added 87.28%	3,230,529 $137 Billion
Q4 2023 Nov 14, 2024	BUY	$20.27 - $42.44 $35 Million - $73.2 Million	1,725,000 New	1,725,000 $73.1 Billion

5.93M

27.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.